Recently, researchers reported 72-week results from a phase 3 trial of biosimilar rituximab, CT-P10 (Truxima), in patients with rheumatoid arthritis (RA), in which they concluded that the product was well tolerated in long-term use and that switching from the reference did not yield differences in safety, efficacy, pharmacodynamics, or immunogenicity.
While the FDA approved Celltrion and Teva’s biosimilar rituximab, CT-P10 (Truxima), for oncology indications only after its sponsors did not pursue indications for nonmalignant diseases due to intellectual property issues, the biosimilar has been studied extensively in rheumatoid arthritis (RA) and is approved for use in RA in the European Union.
Recently, researchers reported 72-week results from a phase 3 trial of the biosimilar in patients with RA, in which they concluded that the product was well tolerated in long-term use and that switching from the reference did not yield differences in safety, efficacy, pharmacodynamics (PD), or immunogenicity.
Previous results from the phase 3 study have been reported elsewhere up to week 24, and the new data present results from an extension period, from week 48 to week 72, after a main treatment period in which patients had received up to 2 treatment courses of the biosimilar or its EU- or US-licensed reference.
In the extension, the 122 patients who had received the biosimilar in the main treatment period continued to receive the biosimilar, and the 47 patients who had received the EU reference switched to the biosimilar. A total of 64 patients who received the US reference in the main period stayed on the same treatment, while 62 who had received the US reference switched to the biosimilar.
At week 72, the mean (SD) change disease activity score in a count of 28 joints (DAS28) with C-reactive protein (CRP) was similar among groups:
Improvement measured by DAS28 with erythrocyte sedimentation rate; the proportion of patients achieving the American College of Rheumatology (ACR)’s criteria for 20%, 50%, and 70% improvement; and the proportion of patients achieving a good or moderate European League Against Rheumatism (EULAR) with CRP response were similar among groups. The proportions of patients achieving remission by ACR and EULAR criteria were also comparable among groups.
B-cell levels were comparable among groups, and there were no discernable differences in median B-cell counts among those who switched and those who did not switch treatments.
Most patients did not develop antidrug antibodies (ADAs) during the main period or the extension. Of the 18 patients who had ADAs during the extension, 16 had ADAs up to the baseline of the extension. The 2 patients who developed new ADAs, 1 in the US reference only group and 1 in the US reference to biosimilar group, did not have neutralizing antibodies; both went on to achieve remission or low disease activity.
The most commonly reported adverse events (AEs) among all groups were upper respiratory tract infections, urinary tract infections, and infusion-related reactions. Most infection AEs were grade 1 or 2 in severity. Five serious AEs were reported in 5 patients, and 1 of these (pneumonia) was considered to be related to rituximab.
These extension period data, say the researchers, show that switching from the US or EU reference rituximab to the biosimilar had no adverse impact on the efficacy, PD, immunogenicity, or safety of rituximab treatment for patients with RA, and that the biosimilar is effective and well tolerated up to week 72.
Reference
Shim SC, Bozić-Majstorović L, Kasay AB, et al. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized phase 3 trial [published online June 10, 2019]. Rheumatology. doi: 10.1093/rheumatology/kez152.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.